Rituximab/graphene oxide composite antibody as well as preparation method and application thereof

A composite technology of rituximab and graphene, which is applied in the direction of antibodies, pharmaceutical formulations, anti-tumor drugs, etc., can solve the problem of weak curative effect of rituximab and achieve the effect of enhancing biological response

Inactive Publication Date: 2016-10-26
XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The invention provides a rituximab / graphene oxide composite antibody to solve the technical problem of weak curative effect of the existing rituximab

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rituximab/graphene oxide composite antibody as well as preparation method and application thereof
  • Rituximab/graphene oxide composite antibody as well as preparation method and application thereof
  • Rituximab/graphene oxide composite antibody as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0038] Another aspect of the present invention provides a method for preparing a rituximab / graphene oxide composite antibody, comprising the following steps: adding rituximab and graphene oxide to a phosphate buffer with a volume percentage of 10-50% solution, shake well at 37-42°C, and react for 4-24 hours to obtain the rituximab / graphene oxide composite antibody.

[0039] Phosphate buffer saline (PBS) is a commonly used reagent in this field, and its pH range is 7.35-7.45. The volume percentage is 10-50% phosphate buffer saline solution, that is, PBS solution, and the addition of water is adjusted on the basis of the original formula to dilute it.

[0040] Rituximab and graphene oxide react under the condition of shaking and shaking, and the two are combined by non-covalent bond to obtain rituximab / graphene oxide composite antibody. And the rituximab / graphene oxide composite antibody can be separated from the phosphate buffer as a solvent, or it can be kept in the phosphate...

Embodiment 1

[0054] Graphene oxide raw materials were purchased from Sigma, purified by dialysis to remove alcohol, and prepared to a concentration of 1mg / ml. Under the condition of Misonix ultrasonic breaker Sonicator 3000 intensity 3.5 in the United States, the ultrasound was continued for 2 hours, the mode worked for 10 seconds, and rested for 5 seconds. Note that the whole process is carried out in a mixture of ice and water. After sonication, filter with a 0.22 μm filter to prepare graphene oxide, measure the final concentration with Nanodrop, and refrigerate for future use.

[0055] Add 1 mg of rituximab and 0.2 mg of graphene oxide into 1 ml of 10% phosphate buffer by volume, shake well at 4°C, and react for 12 hours to obtain rituximab / graphene oxide containing Mixture of complex antibodies.

Embodiment 2

[0057] The difference from Example 1 is that the temperature for preparing the rituximab / graphene oxide composite antibody is 37°C.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention discloses a rituximab/graphene oxide composite antibody as well as a preparation method and an application thereof. The rituximab/graphene oxide composite antibody consists of rituximab and graphene oxide, wherein the rituximab and the graphene oxide are linked by virtue of a non-covalent bonds, so that the composite antibody is formed; and an antineoplastic biological reaction can be enhanced greatly. Compared with the rituximab which has a slight inhibitory effect in vitro, the rituximab/graphene oxide composite antibody can directly kill lymphoma cells.

Description

technical field [0001] The present invention relates to the field of antibodies, in particular to a rituximab / graphene oxide composite antibody. In addition, the present invention also relates to a preparation method and application of the above-mentioned rituximab / graphene oxide composite antibody. Background technique [0002] Targeted therapy refers to drugs or small molecule substances that act on specialized molecules (molecular targeting) to prevent tumor growth, proliferation, and spread. It is also called molecularly targeted therapy, molecularly targeted drugs, and precision medicine. Targeted therapy is different from chemotherapy: (1) Targeted therapy only acts on tumor-related molecules, while chemotherapy inhibits cell metabolism, affects cell cycle, and acts on all rapidly dividing cells, including tumors and normal cells. In other words, the specificity of chemotherapy is relatively poor; (2) Targeted therapy is carefully designed and selected to target cells...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48A61K39/395A61P35/00
CPCA61K39/395
Inventor 罗承科
Owner XIANGYA HOSPITAL CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap